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Abstract
Background: Tuberculosis (TB) chemotherapy clears bacterial burden in the lungs of patients and allows the
tuberculous lesions to heal through a fibrotic process. The healing process leaves pulmonary scar tissue that
can impair lung function. The goal of this study was to identify fibrotic mediators as a stepping-stone to begin
exploring mechanisms of tissue repair in TB.
Methods: Hematoxylin and eosin staining and Masson’s trichrome stain were utilized to determine levels of
collagenization in tuberculous granulomas from non-human primates. Immunohistochemistry was then employed
to further interrogate these granulomas for markers associated with fibrogenesis, including transforming growth
factor-β (TGFβ), α-smooth muscle actin (αSMA), phosphorylated SMAD-2/3, and CD163. These markers were
compared across states of drug treatment using one-way ANOVA, and Pearson’s test was used to determine the
association of these markers with one another.
Results: TGFβ and αSMA were present in granulomas from primates with active TB disease. These molecules were
reduced in abundance after TB chemotherapy. Phosphorylated SMAD-2/3, a signaling intermediate of TGFβ, was
observed in greater amounts after 1 month of drug treatment than in active disease, suggesting that this particular
pathway is blocked in active disease. Collagen production during tissue repair is strongly associated with TGFβ in
this model, but not with CD163+ macrophages.
Conclusions: Tissue repair and fibrosis in TB that occurs during drug treatment is associated with active TGFβ that
is produced during active disease. Further work will identify mechanisms of fibrosis and work towards mitigating
lung impairment with treatments that target those mechanisms.
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Background
With eight million new cases and 1.5 million deaths an-
nually worldwide, tuberculosis (TB) is one of the
humanity’s greatest health threats [1]. Granulomas, the
pathologic hallmark of TB, are well-circumscribed or-
ganized collections of host immune cells that form in
response to the inhalation of aerosols containing Myco-
bacterium tuberculosis (Mtb)—the causative agent of
TB. Although granulomas can function to kill or con-
tain Mtb, they can also serve as a niche for growth and
persistence of the organism [2–4]. Granulomas often
feature a necrotic center and are thus dubbed as necrotiz-
ing or caseous, while granulomas lacking this necrosis are
said to be non-necrotizing. Granulomas feature epithelioid
macrophages, elongated cells with larger nuclei, sur-
rounded by other macrophages and lymphocytes [5].
Bacteria can be found in epithelioid macrophages and in
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caseum [5]. Uncontrolled replication leads to dissemin-
ation of the bacteria and formation of new granulomas.
However, some granulomas can restrain bacterial dissem-
ination or even develop locally sterilizing immunity. As a
result, these granulomas are often fibrotic and can contain
a calcified core (referred to as fibrocalcific lesions) [6]. A
mixture of necrotizing and collagenous lesions is typical
of the secondary pulmonary tuberculosis and is referred
to as fibrocaseous disease [6, 7]. Although the host factors
that lead to control or dissemination of a single granuloma
are unclear, we have demonstrated that various types of
granulomas and outcomes exist within a single non-
human primate, similar to humans [6, 8].
Tissue fibrosis can result from a wound healing re-
sponse that includes fibroblast activation and recruitment,
production of extracellular matrix materials, and distor-
tion of the normal tissue architecture. The most common
extracellular matrix component is collagen I, which is the
most fibrous form of collagen and represents about 84 %
of the collagen produced by fibroblasts [9]. Fibrosis can be
caused by a local inflammatory response, and fibrosis-
related pathogenesis is associated with dysfunction of
many organs, including lungs, liver, and kidneys [10–12].
Transforming growth factor-β (TGFβ) is the main cyto-
kine implicated in fibrogenesis, although other cytokines
are implicated, including TNF, IL-6, IL-10, IL-13, and IL-
17 [13–18]. TGFβ is produced in a latent form (L-TGFβ)
and can be activated through the plasmin protease path-
way, CD36 and thrombospondin (TSP), reactive oxygen
and nitrogen species, hypoxia, low pH, and matrix metal-
loproteases [19]. Active TGFβ utilizes type 1 and 2 TGFβ
receptors, signaling through a variety of intermediaries,
including phosphorylated SMAD-2/3 [20]. Through
these intermediaries, TGFβ stimulates differentiation of
fibroblasts into myofibroblasts that then produce alpha-
smooth muscle actin (αSMA), a key indicator of and
contributor to fibrotic pathogenesis [21]. TGFβ has
been observed and measured in pulmonary fibrosis
and, in the lung, is produced by alveolar macrophages,
fibrocytes, and lung epithelial cells [22–25]. Alveolar
macrophages from humans with pulmonary fibrosis
display an alternatively activated (M2) phenotype, and
induction and maintenance of M2 macrophages is crit-
ical to pathology in pulmonary fibrosis [26]. M2 macro-
phages are also major producers and activators of
TGFβ [24].
Although several types of pulmonary fibrosis have
been characterized and studied, fibrosis in tuberculosis
is not well-understood. Significant pulmonary impair-
ment was observed in 59 % of patients with TB disease
[27], half of whom had less than 50 % of their original
forced vital capacity [27]. This loss of pulmonary func-
tion resulted in 177 subjects losing 1189 disability
adjusted-life years [28]. Lung function does not improve
over the course of chemotherapy [29], and this chronic
impairment increases incrementally with the number of
TB episodes experienced in a progressive manner [29].
The main course of treatment for post-tuberculosis lung
damage is pulmonary rehabilitation, which has mixed re-
sults [30], highlighting the need for more targeted therap-
ies to resolve TB-induced fibrosis and scarring. Since
macrophages produce TGFβ in pulmonary fibrosis, and
are a major cellular component of granulomas [24], mac-
rophages may be important contributors to fibrosis in TB
lesions [31]. The environment of the granuloma may
contain almost all of the conditions that activate TGFβ,
including hypoxia [32], nitrogen radicals [5], and metallo-
proteases [33], so it is likely that the disease process acti-
vates TGFβ locally at the site of infection. Cutaneous TB
lesions in humans have been noted as centers of fibrosis,
with lesions containing active TGFβ [34]. Patients with TB
have peripheral blood monocytes and alveolar macro-
phages that produce and active more TGFβ than cells
from healthy controls [35, 36]. TGFβ has also been ob-
served directly in granulomas from human TB patients by
immunohistochemistry [37].
Drug treatment for M. tuberculosis infection [38, 39] is a
lengthy process that slowly clears bacterial burden in the
lung and induces tissue repair in TB-affected lung. The
factors that promote fibrotic resolution of tuberculous
granulomas are poorly understood. This has been a chal-
lenging topic to address because of difficulties associated
with studying human TB and a lack of appropriate mouse
models demonstrating the granuloma structures seen in
humans. Our laboratory previously published that drug-
treated macaques with TB had fibrotic granulomas, and
the fibrotic granulomas were most often sterile [40],
representing a successful outcome of drug treatment.
Since macaques recapitulate the spectrum of granuloma
types and infection outcomes seen in humans, they repre-
sent a useful system for studying the process of drug-
associated fibrosis. Understanding the fibrotic processes
that occur in TB may provide insights into treatments to
safely resolve residual lung fibrosis during or after drug
therapy. The objective of this study was to determine how
the cell types and molecules associated with pulmonary fi-
brosis differ between granulomas associated with active
TB and fibrotic changes after chemotherapy. This study
will open up further exploration of the fibrogenic mecha-
nisms, with the aim of developing treatments to minima-
lize or reverse scarring after drug treatment.
Results
Macrophages experience spindloid transformation in
tuberculous granulomas
After the original uptake of mycobacterial organisms by
macrophages, a chemokine and cytokine cascade leads to
monocyte recruitment, differentiation of macrophages,
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and epithelioid transformation. The latter is characterized
by a large, plumper, more eosinophilic staining cell with
somewhat elongated, sole-shaped nuclei (Fig. 1, dashed
arrow). In contained tuberculous lesions, especially non-
necrotizing ones that do not expand or infiltrate into adja-
cent bronchial or alveolar airspaces, further change then
occurs globally in the appearance of these cells. Cell bod-
ies become less plump and more streaming in shape, with
nuclei progressing to a more tapered, spindled appearance
(Fig. 1, solid arrow). A similarity between other aspects of
nuclear (e.g., chromatin pattern) and cytoplasmic morph-
ology remains between cells in different stages of this
continuum. Fibroblasts and associated collagen fiber for-
mation (Fig. 1, arrowhead) are seen in both necrotizing
and non-necrotizing lesions, followed by the development
of dense bands and sheets of fibrous connective tissue.
Eosinophils have been linked to promotion of fibrogenesis
[41] but are rarely abundant in lung granulomas in non-
human primates (unpublished observations).
Granulomas exhibit a range of collagen deposition before
and after drug treatment
Our laboratory has previously provided histologic evi-
dence for the resolution of TB pathology after 2 months
of chemotherapy in cynomolgus macaques [40]. We
used Masson’s trichrome staining, a histologic technique
for specifically identifying collagen, on pooled granu-
lomas from two previously published drug studies [40,
42] to confirm our hematoxylin and eosin (H&E)-based
findings on the same set of animals. We examined if
representative lesions have more (Fig. 2a, c, e) or less
(Fig. 2b, d, f ) collagen present by both histological stains.
The more collagenous granuloma from an animal with
active disease exhibits a faint ring of peripheral collagen
deposition (Fig. 2a), which is not uncommon in tubercu-
lous lesions, while less collagen-rich non-fibrotic granu-
lomas lack this peripheral cuff of collagen (Fig. 2b).
After 1 month of drug treatment, some granulomas ex-
hibit a “healing” phenotype [40], as evidenced by a thick-
ening of the peripheral fibrotic cuff and central fibrous
organization (Fig. 2c). Other granulomas lack this degree
of collagenization but still exhibit some central fibrous
organization (Fig. 2d). By 2 months of chemotherapy,
there are many lesions whose phenotype is solidly col-
lagenous (Fig. 2e). There are still lesions though that are
not completely resolved, and these granulomas are char-
acterized as having some central fibrous development
without a robust peripheral cuff (Fig. 2f ). These data
suggest potentially different cellular mechanisms of tis-
sue repair in tuberculosis, with various degrees of col-
lagenization. We then quantified the photomicrographs
for aniline blue-stained collagen to determine how drug
treatment modifies collagen deposition (Fig. 2g). We
found that granulomas from animals with active disease
and 1 month of chemotherapy exhibit a wide range of
collagen deposition (Fig. 2g). After 2 months of drug
therapy, half of the granulomas are highly collagenous,
but the other half displayed lesser degrees of collageniza-
tion (Fig. 2g). To put these data within the context of bac-
terial burden and sterilization, we divided the number of
sterile lung granulomas by the total number of lung
granulomas to get percentages of sterile lung granulomas
for all of the animals in the study (Additional file 1: Figure
S1). We found that the frequency of sterile granulomas
increases as drug therapy progresses (Additional file 1:
Figure S1a) and that this rise is concurrent with a signifi-
cant increase the presence of collagen-rich granulomas
(p = 0.0002; Additional file 1: Figure S1b).
Tuberculous granulomas bear signs of TGFβ-driven fibrosis
We next wanted to determine whether M2 macrophages
and TGFβ were associated with tissue repair. Granulomas
from animals with active disease, 1 month of antibiotic
(ABX) therapy, and 2 months of ABX were analyzed by
multiparameter immunohistochemistry for collagen 1,
phosphorylated (p) SMAD-2/3 (an intermediary of TGFβ
signaling), and CD163 (a marker of M2-polarized macro-
phages in primates [5]) or TGFβ, L-TGFβ, and
αSMA using appropriate controls (Additional file 2: Figure
S2). This approach provides information on the location
and quantity of factors upstream of TGFβ induction and
TGFβ activation. We found that caseous granulomas from
animals with active, untreated disease contained strongly
staining fibrils of collagen I that could be visualized in the
central region of the lesion while pSMAD-2/3+ and
CD163+ cells were present along the periphery of the
structure (Fig. 3a). In similar granulomas from untreated
animals, active TGFβ was present around the necrotic
Fig. 1 Macrophages experience spindloid transformation in
tuberculous granulomas. H&E stained granuloma that demonstrates
spindloid transformation of histiocytes. This figure provides
microhistological examples of: epithelioid transformation of
macrophages with elongated nuclei, dashed arrow, top; tapered,
spindled macrophages further transformed, solid arrow, left; and
collagen deposition, arrowhead, right. Magnification at ×200
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Fig. 2 Granulomas exhibit range of collagen deposition before and after drug treatment. Representative sections of histology from granulomas
pooled from two TB chemotherapy studies [40, 42], each with H&E staining (top panel) and Masson’s trichrome staining (bottom panel) for the
same lesion. a Granuloma from active disease with some peripheral fibrogenesis. b Granuloma from active disease with no apparent collagenization.
c Granuloma from 1-month drug-treated animal with robust peripheral fibrotic cuffing. d Granuloma from 1-month drug-treated animal
with some central fibrous organization. e Fibrotic granuloma from 2-month drug-treated animal. f Granuloma from 2-month drug-treated animal with
pervasive central fibrous organization. g Quantification of all Masson’s trichrome sections. Median pixel intensity was calculated from the blue channel
of each micrograph and plotted by stage of drug therapy. Bars in each column represent medians. Kruskal–Wallis test: p = 0.0285. *p < 0.05
Fig. 3 Tuberculous granulomas bear signs of TGFβ-driven fibrosis. Top panels feature granulomas stained for collagen I (red), phosphorylated
SMAD-2/3 (green), and CD163 (blue). Bottom panels feature granulomas stained for TGFβ (red), L-TGFβ (green), and αSMA (blue). Magnification
×200. Scale bar represents 500 μm. a, b Granulomas from animals with active disease. c, d Granulomas from animals after 1 month of TB chemotherapy.
e, f Granulomas from animals after 2 months of TB chemotherapy
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portion of the lesion (Fig. 3b), an area populated by epi-
thelioid macrophages [5, 43]. Latent TGFβ was observed
throughout this granuloma, and αSMA was strongly
present in a region of robust peripheral fibrosis. After
1 month of drug treatment, collagen I was detected
around the edge of the structure, suggesting mild periph-
eral fibrotic development (Fig. 3c). Strong pSMAD-2/3
staining was interspersed among the CD163+ cells that
were localized towards the center of the structure, a pos-
ition in which they are not normally found during active
disease. Another granuloma from an animal with 1 month
of drug therapy exhibited very little αSMA or active
TGFβ, except minor staining in the exterior and in an
adjacent blood vessel (Fig. 3d). Granulomas from ani-
mals 2 months post-chemotherapy displayed plentiful
collagen I staining, with both peripheral fibrosis and
central fibrotic organization (Fig. 3e). In this particular
lesion, pSMAD-2/3 and CD163 appear to co-localize in
the fibrosis. We found that αSMA is present in a ring
around the periphery of the structure (Fig. 3f ). The ac-
tive and latent forms of TGFβ appear to be intermixed
within the lesion. These data overall indicate that active
TGFβ is present in these granulomas and drives expres-
sion of TGFβ-regulated products including αSMA.
Active Mtb infection and disease activates TGFβ and
suppresses SMAD-2/3 signaling
We quantified median pixel intensity (MPI) from a col-
lection of granulomas to elucidate how latent and ac-
tive TGFβ, αSMA, pSMAD2/3, collagen, and CD163
expression change over the three time points we are
examining. We found an initial decrease in latent TGFβ
levels at the initiation of drug treatment, but un-
changed levels between 1 and 2 months of drug therapy
(Fig. 4a). In contrast, active TGFβ appeared to decline
in animals over the full 2-month course of drug therapy
(Fig. 4b), while the trend in αSMA expression was con-
sistent with trend observed for latent TGFβ (Fig. 4c).
Interestingly, levels of phosphorylated SMAD-2/3 were
higher after 1 month of chemotherapy but then de-
creased by 2 months of antibiotics (Fig. 4d). Relative
amounts of collagen I and CD163 do not change be-
tween following antibiotic treatment (Fig. 4e–f ). These
data further demonstrate the role that active TGFβ is
playing in drug-promoted tissue repair.
We used immunologic and biochemical assays to
confirm our immunohistochemical analysis of TGFβ
and collagen. Consistent with our immunohistochemical
data, enzyme-linked immunosorbent assays (ELISAs) for
Fig. 4 Active Mtb infection and disease activates TGFβ and suppresses SMAD-2/3 signaling. a–f Quantification of IHC. Median pixel intensity (MPI)
was calculated from red, green, and blue color channels of each micrograph and plotted by stage of drug therapy. Bars in each column represent
medians. Kruskal–Wallis test had p values of less than 0.0001 for TGFβ and αSMA, pSMAD-2/3 (0.0006), L-TGFβ (0.0148), and collagen I and CD163
(not significant). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001
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active TGFβ demonstrated greater quantities of TGFβ
in granulomas from animals during active disease and
lesser in animals after 2 months of drug treatment
(Fig. 5a). Collagen levels were measured by hydroxypro-
line assay (Fig. 5b) and were unchanged between
treated and untreated animals, coinciding with our
microscopic data (Fig. 4f ).
TGFβ is strongly associated with collagen I expression
We used our quantitative immunohistochemical data
(Fig. 4) to perform pairwise correlations to identify the
relationships between these factors. At all study time
points, collagen I and pSMAD-2/3 exhibit a robust posi-
tive association (Fig. 6), especially during active disease
and 1 month of drug therapy. In these time points, we
found that over 50 % of the variability in collagen I levels
was explained by pSMAD-2/3 (Pearson’s r > 0.7). In
granulomas from animals with active disease, or 2 months
of drug treatment, there is a weak but significant associ-
ation between pSMAD-2/3 and CD163 (Fig. 6). However,
CD163 and collagen I are not statistically associated at
any time point of the study (Fig. 6). This is in contrast to
active TGFβ, latent TGFβ, and αSMA, which are all
strongly and positively associated with one another at all
time points (Additional file 3: Figure S3).
Discussion
The goal of this study was to identify molecular and cel-
lular markers associated with fibrotic resolution in ex-
perimental tuberculosis infection. Tuberculosis produces
a wide range of pulmonary pathologies through infection
and disease, which typically result in chronic fibrocas-
eous disease [6, 7]. Drug treatment reduces bacterial
burden and allows for tissue repair, although this does
Fig. 5 Biochemical evidence of TGFβ and collagen. a ELISA for active TGFβ. TGFβ in granulomas was converted into pg and then normalized by
the total amount of protein in each granuloma as determined by BCA assay. Wilcoxon signed-rank test was used to compare granulomas from
active disease to granulomas from 2 months of drug treatment. b Hydroxyproline assay. Collagen present in granulomas was determined using
the hydroxyproline assay. Values were converted into pg and then normalized by the total amount of protein in each granuloma as determined
by BCA assay
Fig. 6 TGFβ is strongly associated with the presence of collagen I. IHC
values for each granuloma were plotted against one another to assess
association between collagen I, TGFβ signaling, and M2 macrophages.
Values were transformed, and Pearson’s test for parametric correlation
was used to determine significance. Significant correlations are
denoted by red symbols. Open circles are significant but r < 0.7, while
asterisks indicate that r > 0.7
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not quickly alter the pathology remaining in the lung as
demonstrated by computed tomography in both human
and non-human primates [44]. Chemotherapy addition-
ally leaves individuals vulnerable to relapse; more than
half of smear positive TB cases have been previously
treated for TB [45]. Relapse was originally thought to be
cause by endogenous sources of Mtb remaining after
drug treatment, but 75 % of relapse cases in a high TB
burden cohort were exogenously reinfected [46]. Why is
this population prone to reinfection after successful
chemotherapy? The risk of developing active TB is about
4.5 times higher in patients with chronic interstitial lung
disease and idiopathic pulmonary fibrosis [47, 48]. This
could be due to the specific pathology of fibrotic lung
tissue as it may promote colonization and establishment
of infection [49]. The residual scar tissue left after drug
therapy and loss of normal lung architecture could play
roles in increasing the risk of relapse. Therefore, under-
standing the mechanism of fibrogenesis in TB and
ameliorating tissue damage after drug treatment could
reduce the risk of reinfection and help shrink the pool of
infected individuals.
Several cell types are likely to play significant roles in
driving fibrotic processes in granulomas, but it has been
difficult to identify the specific cells that are the most
important drivers of fibrosis. Histologic assessment can
be used to evaluate the cellular responses to infection
from a morphological perspective and can provide in-
sights into lesion development and resolution. Identify-
ing the cellular origin of some spindle-type cells in
granulomas is not always possible, but histologic exam-
ination can provide important inferences as to whether
these cells arose from epithelioid macrophages or
collagen-producing fibroblasts. Based on our histologic
observations and immunohistochemical analyses, we
hypothesize that collagen-producing fibroblast-like cells
may originate from several sources, and in some cases
not from fibroblasts recruited from nearby tissues, but
from non-fibroblast-like cells that have undergone a
process similar to endothelial–mesenchymal progression.
Additionally, circulating monocyte-derived cells (fibro-
cytes) can have phenotypes reminiscent of the phenotypes
we have identified [50, 51]. Given the ability of some
circulating monocytes to differentiate into fibroblast-like
cells instead of macrophages, the question of whether
subsequent differentiation between macrophages and fi-
broblasts can occur should be considered. The wide range
in collagen presence and the appearance of various collag-
enous phenotypes suggest that different mechanisms for
fibrotic resolution occur in tuberculous granulomas. Some
granulomas manifest both peripheral and central fibrous
organization, while others demonstrate only central col-
lagenization, or none at all. Future studies should seek to
correlate these divergent repair mechanisms to lesion-
specific Mtb burden to determine efficacy of clearance and
elucidate the immunologic processes of each.
Our observations that latent TGFβ changes only slightly
between granulomas from animals with active disease and
drug-treated animals suggest that a pool of latent TGFβ
remains in the lung even after Mtb is cleared. Latent
TGFβ is maintained in the lung epithelium by latent
TGFβ-binding proteins where it can remain until activated
[52]. Our data indicate that conditions within granulomas
activate TGFβ, an anti-inflammatory cytokine associated
with fibrosis (Fig. 7). This molecule exerts biological ac-
tion in the granuloma, as is supported by the presence of
αSMA in direct proportion to TGFβ. The lower levels of
TGFβ and αSMA in granulomas of animals on drug ther-
apy suggest that therapy itself does not activate more
TGFβ and that the amount activated during active TB is
utilized for tissue repair. Interestingly, phosphorylated
SMAD-2/3 is lower during active disease, even though ac-
tive TGFβ levels are high. Since SMAD-2/3 is phosphory-
lated when cells come into contact with active TGFβ [20],
this suggests that live Mtb somehow blocks SMAD-2/3
activation even in the presence of active TGFβ. The pres-
ence of αSMA, also an indicator of the cellular effects of
TGFβ, could be explained by the utilization of alternative
TGFβ-stimulated pathways [53, 54]. The alternative TGFβ
signaling pathways may be prominent in disease, and since
the SMAD-2/3 pathway only becomes used in tissue re-
pair once Mtb is cleared, the SMAD-2/3 pathway may be
preferential for healing and clearance and the alternative
pathways preferential for TB pathogenesis. Collagen I
levels are similar between granulomas with active disease
and drug treatment, suggesting that treatment only pro-
motes and does not exacerbate fibrosis. Collagen I is
strongly associated with active TGFβ; over 50 % of the
variability in levels of collagen I is explained by TGFβ sig-
naling through SMAD-2/3, indicating that active TGFβ is
likely the main molecular driver of fibrosis and tissue re-
pair in tuberculous lesions. CD163 and collagen I are not
associated in this model, implying that the CD163+ mac-
rophages are not major producers of collagen I. Macro-
phages in granulomas are not a uniform population of
cells [5], and other CD163− macrophage subsets could be
responsible for collagen production in the granuloma. Un-
fortunately, there are no pan-macrophage markers for pri-
mates, and our efforts to identify the specific population
of cells responsible for collagen expression are ongoing
[5]. Collagen appears to stream from the epithelioid mac-
rophages into the caseous necrotic center. Interestingly,
this population of cells is not comprised of the M2-
polarized CD163+ macrophages we expected would cor-
relate with fibrosis, but instead appear to be M1-polarized
cells [5], suggesting the capacity of these cells may be
more diverse than previously known. Active TGFβ was
mostly localized in the epithelioid macrophage region of
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the granulomas as well. Alternatively, macrophage-
expressed products could support collagen production by
neighboring fibroblasts. These cells could potentially be
contributors to collagenization, as well as surrounding lung
epithelial cells transformed by active TGFβ. Further work
will include markers for these types of cells and determine
their association with collagen production in the
granuloma.
Conclusions
Fibrosis occurs in TB lesions during and after drug treat-
ment. The goal of this project was to determine the cell
types and molecules associated with fibrosis in non-
human primates with TB. We provide additional evidence
of activated TGFβ being present in lesions from M. tuber-
culosis-infected lung tissue. Collagen production in active
disease and TB chemotherapy is strongly associated with
TGFβ, suggesting its role as the chief cytokine driving tis-
sue repair. Future studies will seek to further explore these
results mechanistically with hopes of developing adjunct




The Institutional Animal Care and Use Committee of
University of Pittsburgh approved all experiments. The
animals were housed and maintained in accordance with
standards established in the Animal Welfare Act and the
Guide for the Care and Use of Laboratory Animals.
Infections
Cynomolgus macaques (4–9 years of age) imported from
China (Valley Biosystems, Sacramento, CA) were used
for these studies (n = 21). Monkeys were infected via
bronchoscope with 25 CFU of M. tuberculosis Erdman
strain. Using published criteria, monkeys were deter-
mined to have active or latent TB by 6–8 months post-
infection and were randomized to treatment or non-
treatment groups; treatment was initiated when monkeys
developed active TB, as determined by clinical and mi-
crobiologic signs [43, 55].
Drug therapy
The samples described in the current study were obtained
from macaques in a previously published study from our
laboratory [40, 42]. Monkeys with active disease were as
follows: untreated (n = 9, 110 granulomas), treated with
isoniazid (INH) and rifampin (RIF) for 1 month (n = 2, 22
granulomas) or 2 months (n = 5, 91 granulomas), or
treated with INH, RIF, and metronidazole (MTZ) for
1 month (n = 3, 154 granulomas) or 2 months (n = 5, 93
granulomas).
Necropsies were performed as previously described [35,
51]. Individual granuloma and lung samples were taken
from each monkey from sites of infection and surrounding
Fig. 7 Model that demonstrates the TGFβ-associated processes explores in this study. The red arrow around active disease represents processes
that activate fibrotic cytokines, which then diminish during the early course of drug therapy (smaller arrows that are less red). αSMA and TGFβ
drop, represented in green, while pSMAD-2/3 appears to rise and fall, in blue. Levels of collagen I do not change, shown in purple
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tissue. Portions of these samples were homogenized into
single cell suspension before storing at −80 °C for ELISA
and hydroxyproline assays, while another portion was
formalin-fixed paraffin-embedded for histology.
H&E staining
Formalin-fixed paraffin-embedded tissue sections were cut
and stained with Harris hematoxylin modified (Sigma-Al-
drich, St. Louis, MO) and eosin Y solution (Sigma-Aldrich,
St. Louis, MO). Slides were deparaffinized in deionized
water. Slides were then stained with hematoxylin for
3 min. Slides were rinsed under running tap water, rinsed
with 70 % ethanol, and then stained with eosin for 3 min.
Slides were rinsed and dehydrated in ethanol, cleared in
xylene, and then mounted. Criteria for characterizing
granulomas were based on size and shape, type of granu-
loma, and cellular composition. A veterinary pathologist
who is an expert in macaque tuberculosis (ECK) performed
all histologic analyses.
Masson’s trichrome
Formalin-fixed paraffin-embedded tissue sections were
stained with Masson’s trichrome to identify connective tis-
sue, muscle, and collagen fibers (Sigma-Aldrich, St. Louis,
MO). Slides were deparaffinized to deionized water. Slides
were then immersed in Bouin’s solution overnight at room
temperature to intensify the subsequent staining. Slides
were washed with tap water then stained with Harris
hematoxylin solution (Sigma-Aldrich, St. Louis, MO) for
5 min. Slides were washed again in running tap water for
5 min, rinsed in deionized water, and stained in Biebrich
scarlet-acid fuchsin for 5 min. Slides were rinsed in deion-
ized water and placed in phosphotungstic and phospho-
molybdic acid solution for 5 min. Slides were moved to
Aniline Blue solution for 5 min and then placed in 1 %
acetic acid solution for 2 min. Slides were rinsed in deion-
ized water, dehydrated through alcohol, cleared in xylene,
and then mounted.
IHC
Tissue sections were stained for collagen I (rabbit
polyclonal, Abcam, Cambridge, MA, 1:50 dilution),
pSMAD-2/3 (goat polyclonal, Santa Cruz Biotechnol-
ogy, Dallas, TX, 1:10 dilution), CD163 (mouse clone
10D6, Neomarkers, Fremont, CA, 1:30 dilution), L-
TGFβ (goat polyclonal, R&D Systems, Minneapolis,
MN, 1:10 dilution), TGFβ (chicken polyclonal, R&D
Systems, Minneapolis, MN, 1:10 dilution), and αSMA
(mouse clone 1A4, Thermo Fisher, Pittsburgh, PA,
1:100 dilution). Antigen retrieval and staining were
done as previously described [5]. Briefly, formalin-fixed
paraffin-embedded tissues samples were deparaffinized
in xylene and rehydrated in ethanol. Samples were then
placed into a pressure cooker with boiling antigen
retrieval buffer (Tris–HCl, EDTA, Tween-20) for 7 min.
After allowing for the slides to cool, the sections were
blocked with 2 % fetal bovine serum in phosphate-
buffered saline for 30 min. Antibodies and fluorescent
tags were incubated on each sample for 1 h with washes
in between with phosphate-buffered saline with 0.2 %
Tween-20. Prolong Gold Mounting Medium with DAPI
(Invitrogen) was then applied to the slides, which were
then cured in the dark overnight before being imaged.
Quantification of histology
Trichrome- and H&E-stained sections were imaged
using Provis fluorescent microscope (Olympus Amer-
ica, Center Valley, PA) and fluorescently stained slides
visualized with a FluoView 1000 confocal microscopes
(Olympus). For images used for quantitative imaging,
care was taken to keep the camera settings constant be-
tween granulomas and animals. These images were
then saved as 24-bit TIFF files and read into the lan-
guage R via the package “EBImage” from Bioconductor
(http://www.bioconductor.org/packages/release/bioc/html/
EBImage.html). For the trichrome slides, the blue channel
only was isolated. Red, green, and blue channels were
pulled from the immunohistochemistry (IHC) slides.
The median pixel intensity for each channel was then
saved and exported to Microsoft Excel (Microsoft,
Redmond, WA).
ELISAs
Active TGFβ-1 in granuloma homogenates was measured
by using a commercial ELISA (eBioscience, San Diego,
CA) according to the manufacturer’s instructions. Briefly,
a high-affinity protein-binding plate was coated with a
capture antibody overnight and blocked with assay diluent
for an hour before adding standards and undiluted granu-
loma homogenates for overnight incubation. TGFβ was
detected the next day using a biotinylated detection anti-
body and streptavidin-HRP, and the absorbance was im-
mediately measured at 450 nm. Total protein of the same
samples was quantified by Pierce BCA Protein Assay
(Thermo Scientific, Pittsburgh, PA), where granuloma ho-
mogenates were added to BCA Working Reagent, and the
absorbance measured at 562 nm after 30 min at 37 °C.
Levels of TGFβ were normalized to total protein in granu-
loma homogenates.
Hydroxyproline assay
Collagen was detected in homogenized granulomas by
using a commercial hydroxyproline kit (Sigma-Aldrich,
St. Louis, MO). Briefly, samples were mixed with hydro-
chloric acid and hydrolyzed at 120 °C for 3 h. These
samples and standards were then transferred to a 96-
well plate and dried. Chloramine T/oxidation buffer was
added to wells and incubated at room temperature for
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5 min. To this, diluted DMAB reagent was added and
incubated at 60 °C for 90 min. Absorbance at 560 nm
was then measured. Levels of collagen were normalized
to total protein in granuloma homogenates.
Statistics
Quantitative data from Masson’s trichrome staining and
immunohistochemical staining were visualized using
Prism (Graphpad, La Jolla, CA). Analysis of these data
was done using the tests indicated, typically a one-way
ANOVA and a multiple comparison test for either para-
metric or non-parametric data. p values were significant
if less than 0.05. Further analysis of the immunohisto-
chemical staining was performed with JMP (SAS, Cary,
NC). Correlations between markers in histological stains
were performed using the multivariate function, and scat-
ter plots were generated. Significance was determined
using pairwise correlations with the strength of the rela-
tionship given as Pearson’s r.
Additional files
Additional file 1: Figure S1. Antibacterial chemotherapy promotes
collagen-associated bacterial clearance. a The number of lung granu-
lomas with viable bacterial growth were divided by the total number of
lung granulomas and plotted for each animal in the three groups. Each
dot represents one animal. Bars represent medians. b The median of the
median pixel intensity of the aniline blue staining was determined. This
was then plotted against the percent of lung granulomas with viable
bacteria. Significance of the interaction between percent of Mtb + lung
granulomas and collagen staining (p) and strength of interaction (R2) are
shown. Each dot represents one animal, and colors match the colors of
the treatment groups in part A of this figure. Dotted lines represent 95 %
confidence intervals. (TIF 271 kb)
Additional file 2: Figure S2. Negative and positive controls for
immunohistochemistry. Left panels feature negative controls for IHC and
right panels feature blood vessels, which should serve as bright signals
for most of the markers. Negative controls did not receive primary
antibodies, but received secondary antibodies and were imaged using
the same settings as the slides for the study. a-b Negative control and
blood vessel for the first panel. c-d Negative control and blood vessel
using the second panel. (TIF 7053 kb)
Additional file 3: Figure S3. Active TGFβ is highly associated with its
latent form and αSMA. IHC values for each granuloma were plotted
against one another to assess association between TGFβ, L-TGFβ, and
αSMA—which is produced by cells activated by TGFβ. Values were
transformed, and Pearson’s test for parametric correlation was used to
determine significance. Significant correlations are denoted by red
symbols. Open circles are significant but r < 0.7, while asterisks indicate
that r > 0.7. (TIF 843 kb)
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